more

Sanofi (SNY)

(Real Time Quote from BATS)

$51.61 USD

+0.35 (0.68%)

Updated Nov 7, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Zacks News

BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research Published on April 26,2019

BioMarin's (BMRN) earnings and revenues surpass estimates in the first quarter.

biotechs

Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales

by Zacks Equity Research Published on April 26,2019

Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.

pharmaceuticals

Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study

by Zacks Equity Research Published on April 17,2019

Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.

biotechs

Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth

by Zacks Equity Research Published on April 09,2019

Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.

biotechs

Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

by Zacks Equity Research Published on April 09,2019

Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

biotechs

Inovio Closes Enrollment in Brain Cancer Study Before Time

by Zacks Equity Research Published on April 02,2019

Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

biotechs

Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

by Zacks Equity Research Published on April 01,2019

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

pharmaceuticals

AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

by Zacks Equity Research Published on March 28,2019

AstraZeneca's (AZN) Forxiga gets approval in Japan for type I diabetes.

pharmaceuticals

Lilly (LLY) Signs New Immunology Deal With Private Biotech

by Zacks Equity Research Published on March 27,2019

Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.

pharmaceuticals

Ascendis Pivotal Growth Hormone Deficiency Study Data Positive

by Zacks Equity Research Published on March 25,2019

Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.

biotechs

Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

by Zacks Equity Research Published on March 25,2019

FDA issues complete response letter for Lexicon Pharmaceuticals (LXRX) and partner Sanofi's marketing application for type I diabetes candidate, Zynquista.

biotechs

AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

by Zacks Equity Research Published on March 25,2019

AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

pharmaceuticals

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research Published on March 22,2019

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

biotechs

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

by Zacks Equity Research Published on March 20,2019

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

biotechs

Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

by Zacks Equity Research Published on March 18,2019

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

biotechs

Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

by Zacks Equity Research Published on March 18,2019

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

biotechs

Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

by Zacks Equity Research Published on March 13,2019

Key highlights of the past week are regulatory and pipeline developments.

biotechs

Should Value Investors Consider Sanofi (SNY) Stock Now?

by Zacks Equity Research Published on March 13,2019

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

SNYPositive Net Change

Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

by Zacks Equity Research Published on March 12,2019

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

biotechs

Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

by Zacks Equity Research Published on March 11,2019

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.